Upperton Pharma Solutions, a UK-based contract development and manufacturing organisation (CDMO) has successfully completed a Medicines and Healthcare products Regulatory Agency (MHRA) inspection at its new GMP manufacturing facility in Nottingham, UK.
The 50,000 sqft development and production facility was commissioned, built and inspected within 18 months, and can now support the development of nasal, oral and pulmonary pharmaceutical products for Phase I, II and III clinical trials.
CEO of Upperton Pharma Solutions, Nikki Whitfield said: “We have been conducting manufacturing scale-up activities since the start of the year, following the installation of the larger scale solid oral dosage form process trains. This validation from the MHRA gives us the green light for our GMP facility to support clients right through to late-phase clinical manufacture and product registration.”
Boosting manufacturing capabilities with novel machinery
The completion of the MHRA inspection allows the company to transition from R&D to GMP manufacturing and commercialisation at one facility, with the equipment lineup able to handle batch sizes of up to 250kg.
Upperton Pharma Solutions can also work with a variety of dosage forms, including solids, liquids, semi-solids and OINDPs.
Director of Clinical Manufacturing Paul Kelsall stated: “This is a dedication to the tremendous hard work our colleagues have put in to achieve the targets and aspirations of our business. We are looking forward to working with our clients and offering services from early-stage development through to late-stage clinical manufacture and Product Registration. These are exciting times for Upperton as we continue to move forward and expand our capabilities.”